<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372371">
  <stage>Registered</stage>
  <submitdate>16/02/2017</submitdate>
  <approvaldate>20/02/2017</approvaldate>
  <actrnumber>ACTRN12617000253303</actrnumber>
  <trial_identification>
    <studytitle>Can placebo pills improve well-being even when you know you're taking a placebo?</studytitle>
    <scientifictitle>Open-label placebo administration and well-being in healthy participants</scientifictitle>
    <utrn>U1111-1193-1778 </utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Well-being</healthcondition>
    <healthcondition>Sleep quality</healthcondition>
    <healthcondition>Physical symptoms</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Open-label placebo administration (1 placebo pill per day versus 4 placebo pills per day) for 5 days compared to a no treatment control condition. Adherence will be assessed via self-report at follow-up after completion of the course of placebo pills (day 6). </interventions>
    <comparator>No treatment control condition - control participants will not take placebo pills and will be observation only through completion of study questionnaires </comparator>
    <control>Active</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Psychological well-being (DASS-21; Lovibond &amp; Lovibond, 1995; WEMWBS; Tennant et al., 2007)</outcome>
      <timepoint>Follow-up 6 days post-randomisation (at completion of the 5-day course of placebo pills)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Sleep quality (PSQI, Buysse et al., 1989)</outcome>
      <timepoint>6 days post-randomisation (at completion of the 5-day course of placebo pills)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Physical symptoms (SHC; Eriksen, Ihlebaek &amp; Ursin, 1999)</outcome>
      <timepoint>6 days post-randomisation (at completion of the 5-day course of placebo pills)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adherence to placebo treatment - assessed using brief self-report measures (number of pills missed, visual analog scale)</outcome>
      <timepoint>6 days post-randomisation (at completion of the 5-day course of placebo pills)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participants will be healthy undergraduate students</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Lactose intolerance</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment via sealed opaque envelopes</concealment>
    <sequence>Simple randomisation table created by computer software (Excel) </sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>3-way ANCOVA assessing primary outcomes across groups, controlling for baseline</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>27/02/2017</anticipatedstartdate>
    <actualstartdate>7/03/2017</actualstartdate>
    <anticipatedenddate>26/05/2017</anticipatedenddate>
    <actualenddate>29/03/2017</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>92</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate>2/06/2017</anticipatedlastvisitdate>
    <actuallastvisitdate>6/04/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <postcode>2052 - Unsw Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Kate Faasse</primarysponsorname>
    <primarysponsoraddress>School of Psychology
UNSW Sydney
NSW 2052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of New South Wales</fundingname>
      <fundingaddress>School of Psychology
UNSW Sydney
NSW 2052</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate the role of dose in open-label placebo administration.  Recent studies have found that open-label placebo treatments are effective in improving symptoms of IBS, depression, ADHD, and low-back and migraine pain. These findings suggest the possibility of generating a placebo effect without deception. Participants will be recruited to take part in a study investigating the effect of open-label placebo administration on well-being and randomly assigned to one of three conditions: no-treatment control, low dose (1 pill per day), or high dose (4 pills per day) placebo administration. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate>10/02/2017</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Kate Faasse</name>
      <address>School of Psychology
UNSW Sydney
NSW 2052</address>
      <phone>+61293850364</phone>
      <fax />
      <email>k.faasse@unsw.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kate Faasse</name>
      <address>School of Psychology
UNSW Sydney
NSW 2052</address>
      <phone>+61293850364</phone>
      <fax />
      <email>k.faasse@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kate Faasse</name>
      <address>School of Psychology
UNSW Sydney
NSW 2052</address>
      <phone>+61293850364</phone>
      <fax />
      <email>k.faasse@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>